Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 2/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | FUT8 | Q9BYC5 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA6 | P23280 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11224616 | 0.91 | APEX1 (0.49) | APEX1NT5EPRMT1ALDH1A1CYP2C9 | |
| SCHEMBL16560637 | 0.83 | APEX1 (0.46) | APEX1NT5EPRMT1ALDH1A1CYP2C9 | |
| SCHEMBL10174724 | 0.83 | APEX1 (0.43) | APEX1NT5EPRMT1ALDH1A1CYP2C9 | |
| SCHEMBL16560634 | 0.82 | APEX1 (0.53) | APEX1NT5EALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL16560638 | 0.81 | APEX1 (0.49) | APEX1NT5EPRMT1ALDH1A1CYP2C9 | |
| SCHEMBL10938751 | 0.81 | APEX1 (0.46) | APEX1NT5EALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL14087146 | 0.80 | CA12 (0.39) | APEX1ALDH1A1CYP2C9CYP2C19HSD17B10 | |
| SCHEMBL16557824 | 0.79 | APEX1 (0.43) | APEX1NT5EPRMT1ALDH1A1CYP2C9 | |
| SCHEMBL7753503 | 0.78 | CA12 (0.45) | APEX1MEN1KMT2ACA12CA1 | |
| SCHEMBL11230352 | 0.78 | APEX1 (0.49) | APEX1NT5EPRMT1ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228535-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2021-07-29 | — | — | US | disclosed |
| US-10959979-B2 | Small molecules against cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2021-03-30 | — | — | US | disclosed |
| US-20200268709-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2020-08-27 | — | — | US | disclosed |
| US-10646465-B2 | Small molecules against cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2020-05-12 | — | — | US | disclosed |
| US-20190240188-A1 | SMALL MOLECULES AGAINST CANCER | ALONBIO LTD. (IL) | 2019-08-08 | — | — | US | disclosed |
| WO-2017103931-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10959979-B2 | Small molecules against cancer | CCL2, CXCR2, CCL5 | APEX1 3020/4885NT5E 1942/4885PRMT1 2106/4885 |
| US-20210228535-A1 | SMALL MOLECULES AGAINST CANCER | CCL2, CXCR2, CCL5 | APEX1 3020/4885NT5E 1942/4885PRMT1 2106/4885 |
| US-10646465-B2 | Small molecules against cancer | CCL2, CXCR2, CCL5 | APEX1 3020/4885NT5E 1942/4885PRMT1 2106/4885 |
| US-20200268709-A1 | SMALL MOLECULES AGAINST CANCER | CCL2, CXCR2, CCL5 | APEX1 3020/4885NT5E 1942/4885PRMT1 2106/4885 |
| US-20190240188-A1 | SMALL MOLECULES AGAINST CANCER | CCL2, CXCR2, CCL5 | APEX1 3020/4885NT5E 1942/4885PRMT1 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.